A lactotransferrin single nucleotide polymorphism demonstrates biological activity that can reduce susceptibility to caries

Infection and Immunity

Volumn 81, Issue 5, 2013, Pages 1596-1605

  Fine, Daniel H ^a   Toruner, Gokce A ^b   Velliyagounder, Kabilan ^a   Sampathkumar, Vandana ^a   Godboley, Dipti ^a   Furgang, David ^a  

^a RUTGERS SCHOOL OF DENTAL MEDICINE   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; LACTOFERRIN; LYSINE; SALIVA PROTEIN;

ACTINOMYCES VISCOSUS; ADULT; AGGRESSIVE PERIODONTITIS; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BIOLOGICAL ACTIVITY; CLINICAL ARTICLE; COLUMN CHROMATOGRAPHY; DENTAL CARIES; DISEASE PREDISPOSITION; DNA SEQUENCE; FEMALE; FUSOBACTERIUM NUCLEATUM; GENOTYPE; HUMAN; IN VITRO STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SALIVA; SALIVA ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STREPTOCOCCUS GORDONII; STREPTOCOCCUS MITIS; STREPTOCOCCUS MUTANS; STREPTOCOCCUS SANGUINIS; VEILLONELLA PARVULA; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANTI-INFECTIVE AGENTS; DENTAL CARIES; DENTAL CARIES SUSCEPTIBILITY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LACTOFERRIN; LYSINE; POLYMORPHISM, SINGLE NUCLEOTIDE; SALIVA; STREPTOCOCCUS MUTANS;

EID: 84877810753     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01063-12     Document Type: Article

References (31)

1. Mandel ID. 2002. Oral infections: impact on human health, well-being, and health-care costs. Compend. Contin. Educ. Dent. 23:403-406.
2. Satcher D. 2000. Oral health in America: a report of the Surgeon General, p 616-623. Department of Health and Human Services, NIH, Rockville, MD.
3. Mandel ID. 1987. The functions of saliva. J. Dent. Res. 66:623-627.
4. Scannapieco FA. 1994. Saliva-bacterial interactions in oral microbial ecology. Crit. Rev. Oral Biol. Med. 5:203-248.
5. Loesche WJ. 1986. Role of Streptococcus mutans in human dental decay. Microbiol. Rev. 50:353-380.
6. Groenink J, Walgreen-Weterings E, Nazmi K, Bloscher JG, Veerman EC, van Winkelhoff AJ, Nieuw Amerongen AV. 1999. Salivary lactoferrin and low-Mr mucin MG2 in Actinobacillus actinomycetemcomitansassociated periodontitis. J. Clin. Periodontol. 26:269-275.
7. Liu B, Rayment SA, Oppenheim FG, Offner GD, Fives-Taylor P, Troxler RF. 2002. Interaction of salivary mucin MG2, its recombinant N-terminal region and synthetic peptide with Actinobacillus actinomycetemcomitans. J. Periodontal Res. 37:416-424.
8. Arnold RR, Brewer M, Gauthier JJ. 1980. Bactericidal activity of human lactoferrin: sensitivity of a variety of organisms. Infect. Immun. 28:893-898.
9. Lassiter MO, Newsome AL, Sams LD, Arnold RR. 1987. Characterization of lactoferrin interaction with Streptococcus mutans. J. Dent. Res. 66:480-485.
10. Kalmar JR, Arnold RR. 1988. Killing of Actinobacillus actinomycetemcomitans by human lactoferrin. Infect. Immun. 56:2552-2557.
11. Velliyagounder K, Kaplan JB, Furgang D, Legarda D, Diamond G, Parkin RE, Fine DH. 2003. One of two human lactoferrin variants exhibits increased antibacterial and transcriptional activation activities and is associated with localized juvenile periodontitis. Infect. Immun. 71:6141-6147.
12. Azevedo LF, Pecharki GD, Brancher JA, Cordeiro CA, Jr, Medeiros KG, Antunes AA, Arruda ES, Werneck RI, de Azevedo LR, Mazur RF, Moyses ST, Faucz FR, Trevilatto PC. 2010. Analysis of the association between lactotransferrin (LTF) gene polymorphism and dental caries. J. Appl. Oral Sci. 18:166-170.
13. Fine DH, Furgang D, Goldman D. 2007. Saliva from subjects harboring Actinobacillus actinomycetemcomitans kills Streptococcus mutans in vitro. J. Periodontol. 78:518-526.
14. Fine DH, Tabak L, Stevens R. 1977. Affinity chromatography of antiserum to a gram negative organism. J. Immunol. Methods 16:91-96.
15. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
16. Helmerhorst EJ, Oppenheim FG. 2007. Saliva: a dynamic proteome. J. Dent. Res. 86:680-693.
17. Rudney JD. 1989. Relationships between human parotid saliva lysozyme lactoferrin, salivary peroxidase and secretory immunoglobulin A in a large sample population. Arch. Oral Biol. 34:499-506.
18. Rudney JD. 1995. Does the variability in salivary protein concentrations influence oral microbial ecology and oral health? Crit. Rev. Oral Biol. Med. 6:343-367.
19. Fine DH, Goldberg D, Karol R. 1984. Caries levels in patients with juvenile periodontitis. J. Periodontol. 55:242-246.
20. Loe H, Brown LJ. 1991. Early onset periodontitis in the United States of America. J. Periodontol. 62:608-616.
21. Hancock RE, Chapple DS. 1999. Peptide antibiotics. Antimicrob. Agents Chemother. 43:1317-1323.
22. Brogden KA. 2005. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. 3:238-250.
23. Zasloff M. 2002. Antimicrobial peptides of multicellular organisms. Nature 415:389-395.
24. Fine DH, Furgang D, McKiernan M, Rubin M. 2012. Can salivary activity predict periodontal breakdown in A. actinomycetemcomitans infected adolescents? Arch. Oral Biol. http://dx.doi.org/10.1016/j .archoralbio.2012.10.009.
25. Plaut AG, Qui J, Grundy F, Wright A. 1992. Growth of Haemophilus influenzae in human milk: synthesis, distribution, and activity of IgA protease as determined by study of IgA and mutant IgA cells. J. Infect. Dis. 166:43-52.
26. Naidu SS, Svensson U, Kishore AR, Naidu AS. 1993. Relationship between antibacterial activity and porin binding of lactoferrin in Escherichia coli and Salmonella typhimurium. Antimicrob. Agents Chemother. 37:240-245.
27. Chapple DS, Hussain R, Joannou CL, Hancock RE, Odell E, Evans RW, Siligardi G. 2004. Structure and association of human lactoferrin peptides with Escherichia coli lipopolysaccharide. Antimicrob. Agents Chemother. 48:2190-2198.
28. Bortner CA, Miller RD, Arnold RR. 1986. Bactericidal effect of lactoferrin on Legionella pneumophila. Infect. Immun. 51:373-377.
29. Nishimura E, Eto A, Kato M, Hashizume S, Imai S, Nisizawa T, Hanada N. 2004. Oral streptococci exhibit diverse susceptibility to human b defensin-2: antimicrobial effects of hBD-2 on oral streptococci. Curr. Microbiol. 48:85-87.
30. Joly S, Maze C, McCray PB, Guthmiller JM. 2004. Human b-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J. Clin. Microbiol. 42:1024-1029.
31. Singh PK, Parsek MR, Greenberg PE, Welsh MJ. 2002. A component of innate immunity prevents bacterial biofilm development. Nature 417: 552-555.